Bufab Group: Interim report January - June 2018 Continued

New Post Public Reply Private Reply Replies (0) Message Board

Newer Older

News Desk 2018

Jul 19, 2018 at 3:30 AM 56

Bufab Group: Interim report January - June 2018

Continued strong growth and improved margin

Second quarter 2018

Net sales rose by 19 percent to SEK 980 million (823). Organic growth was 9 percent
Order intake increased 18 percent and was in line with net sales
Operating profit (EBITA) rose to SEK 98 million (78) and the operating margin to 10.0 percent (9.5)
Earnings per share were SEK 1.78 (1.41)

January - June 2018

Net sales rose by 18 percent to SEK 1,925 million (1,638). Organic growth was 10 percent
Order intake was in line with net sales
Operating profit (EBITA) rose to SEK 204 million (170) and the operating margin was 10.6 percent (10.4)
Earnings per share rose to SEK 3.77 (3.05)

The Group in brief

	*Quarter 2*		D	*Jan-June*			D	*12-months* *rolling*	*Full year*
*SEK million*	*2018*	2017	%		*2018*	2017	%	*2017/18*	2017
Order intake	979	833	18		1,923	1,644	17	3,535	3,256
Net sales	980	823	19		1,925	1,638	18	3,488	3,201
Gross profit	282	232	22		559	471	19	1,005	917
%	*28.8*	28.2			*29.0*	28.7		*28.8*	28.6
Operating expenses	-184	-154	19		-355	-301	18	-660	-606
%	*18.8*	18.7			*18.4*	18.4		*18.9*	18.9
Operating profit (EBITA)	98	78	26		204	170	20	344	310
%	*10.0*	9.5			*10.6*	10.4		*9.9*	9.7

Operating profit	96	77	25		200	167	20	337	304
%	*9.8*	9.4			*10.4*	10.2		*9.7*	9.5
Profit after tax	67	54	24		142	116	22	239	213
Earnings per share, SEK	1.78	1.41	26		3.77	3.05	24	6.33	5.61

CEO's overview

The favourable performance that marked the beginning of the year continued during the second quarter. Solid growth at 19 percent was driven by acquisitions, increased market shares and favourable underlying growth, but also by positive calendar effects.

Segment International accelerated the excellent earnings trend that we have witnessed in recent years. Through strengthened market shares in most markets and through successful acquisitions, we achieved growth of 25%. The gross margin improved significantly due to currency effects and price increases that exceeded the material-driven cost increases. It was also satisfying that the growth did not cause a corresponding rise in operating expenses. In total, operating profit grew by more than 50 percent. These successes give us confidence and scope for continued investment in the segment.

On the other hand, Segment Sweden experienced a poorer earnings trend during the quarter. Growth was good, but the gross margin was lower than earlier in the year and in 2017. This means that we have not fully succeeded in offsetting the continued negative trend for the SEK and raw materials prices through price increases to customers. However, work continues aiming at a strong and stable gross margin over time, regardless of external factors. In addition, the segment's cost level for the quarter was too high, partly due to adjustment of a and currency effects. Overall, operating profit declined, a development with which we cannot be satisfied.

The uncertainty regarding the economic development increased during the quarter, among other factors due to the fear of a trade war. This is reflected, for example, in a somewhat weaker purchasing managers' index, but has not yet made an impact on Bufab's order intake. At the same time as we are watchful for signs of a downturn, our ambition is to increase our market share at the same rate as previously, or faster.

We need to strengthen our gross margin through further price increases. In addition, we need to work to ensure that operating expenses do not increase further as a share of sales, despite the significant investments we are making in our "Leadership" programme. This requires comprehensive efficiency measures in the business in general.

For Bufab in its entirety, we are satisfied with the quarter and with the first half of 2018. Healthy growth, an improved margin and Bufab's best six-month profit to date are indications that our strategy for organic and acquisition-driven growth is working. Reinforced by this, we will continue to increase the investments in our strategy. The aim is to be the leading company in our industry by 2020.

Jörgen Rosengren President and CEO

CONTACT

Jörgen Rosengren

CEO +46,370 69 69 00 jorgen.rosengren@bufab.com

Marcus Andersson CFO +46,370 69 69 66 marcus.andersson@bufab.com

This information is such that Bufab AB (publ) is obliged to disclose in accordance with the EU's Market Abuse Regulation. The information was submitted for publication by the aforementioned contacts on 19 July 2018 at 7:30 a.m. CET.

Bufab Holding AB (publ) Box 2266 SE-331 02 Värnamo, Corp. Reg. No. 556685-6240 Tel: +46 370 69 69 00 Fax +46 370 69 69 10 www.bufab.com

Attachment

Delårsrapport Q2 2018 - FINAL ENG.pdf

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Health Hit by FTC Claims and Class Action

Hims Faces Harsh Lessons With FTC Lawsuit There's trouble brewing in the world of telehealth, and Hims & Hers Health (NYSE: HIMS) is right at the eye of the storm. They've gone from a darling of digital health to a pariah faster than you can say 'data breach.' On July 29, 2026, they took a hit so hard you’d think the company stepped into the ring with a heavyweight...

U.S. Court Ruling Opens Market for Cocrystal's CrysQnol™

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

Regeneron Faces Class Action Over Tumultuous Trial Results

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Insurance 101: Know Your Limits and Deductibles

It might not exactly be cocktail party fodder, but boy, skipping on understanding your homeowners insurance is a shortcut straight to financial hell. You’re living in St. Albans, WV, in a home that’s probably your biggest investment. Let’s talk about this before you find yourself in a mess you should've seen coming. Why Coverage Limits Matter a Whole Lot Listen up,...

vivo and UNESCO Unite Youth for Nature Stories

Young Creators Explore Nature Through a New Lens Pontremoli, Italy just became the backdrop for an extraordinary gathering of young visionaries. From August 31 to September 5, UNESCO’s Man and the Biosphere (MAB) Programme and vivo wrapped their 2026 Capture the Future initiative in the lush landscapes of the Appennino Tosco Emiliano Biosphere Reserve. It’s one thing...

Fosun Pharma Hits the Buyback Button: What's Next?

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Nurminen Logistics Doubles Sweden–Italy Rail Capacity

Nurminen Logistics Betting Big on Rail Expansion Feeling the pulse of the logistics world is much like trying to catch lightning in a bottle, but Nurminen Logistics seems to have found its rhythm. They're ramping up their services between Sweden and Italy, leveraging rail to push the envelope. Come October, they're doubling down from one to two weekly departures, giving...

ACG Moves to Acquire Ke?kek for $7.85M Gold Venture

Here's the scoop: ACG Metals Limited is stepping up the game, attempting to snag the Ke?kek gold project in a deal worth up to $7.85 million. This move, they say, is all about bolstering the future of their gold production—and squeezing every ounce out of that Gediktepe facility in Türkiye. It's like squeezing juice from a lemon that's still got a bit of life left....

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Consumer365 Highlights Happy Head's Personalized Hair Solutions

Tailored Hair Loss Solutions by Happy Head Imagine trying to fit a square peg in a round hole. That's what one-size-fits-all approaches often feel like in the world of hair loss treatments. Happy Head, recognized by Consumer365, takes that notion and turns it on its head, offering personalized minoxidil formulations for women. The key word here is personalized. More Than...